Kalaany and Sabatini had shown in NOD-SCID (non-obese diabetic, severe combined immunodeficient) mice that xenografted tumors with constitutive activation of AKT by either gains in PIK3CA or loss of PTEN are resistant against CR, and insensitive to insulin and IGF-1 treatment in vitro
[PMID: 25050016] PubMed record related to this compound for laboratory literature review
That part doesnt change based on which peptide you choose.If you want that kind of structured approach, physician-led evaluation, baseline and ongoing IGF-1 monitoring, honest sourcing, and a protocol matched to your goal rather than a default, thats the model TRTMD is built around
All data are expressed as mean S.E.M
F., Laimer, M., Kaser, S., Ritsch, A., Sandhofer, A., Weiss, H., Aigner, F., & Patsch, J